Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44416   clinical trials with a EudraCT protocol, of which   7423   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer

    Summary
    EudraCT number
    2011-002577-33
    Trial protocol
    GB  
    Global end of trial date
    21 Oct 2025

    Results information
    Results version number
    v1(current)
    This version publication date
    01 Nov 2026
    First version publication date
    01 Nov 2026
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    ICR-CTSU/2011/10031
    Additional study identifiers
    ISRCTN number
    ISRCTN98387754
    US NCT number
    NCT01993979
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    Sponsor Identification Number: CCR3675, ICR-CTSU Protocol Number:: ICR-CTSU/2011/10031
    Sponsors
    Sponsor organisation name
    The Institute of Cancer Research Clinical Trials and Statistics Unit
    Sponsor organisation address
    32 Oakleaf Avenue, Sutton, United Kingdom, SM25GP
    Public contact
    Rebecca Lewis, Institute of Cancer Research, ctsu@icr.ac.uk
    Scientific contact
    Rebecca Lewis, Institute of Cancer Research, ctsu@icr.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 Feb 2022
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    07 Feb 2022
    Global end of trial reached?
    Yes
    Global end of trial date
    21 Oct 2025
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To determine whether adjuvant combination chemotherapy improves disease-free survival for patients with resected histologically confirmed muscle invasive (pT2-T4, N0-3) or node positive upper tract urothelial carcinoma.
    Protection of trial subjects
    Detailed participant information materials and the opportunity to ask questions prior to enrolment; close monitoring and management of toxicities, particularly during the treatment phase; adherence to relevant data protection regulations; oversight of emerging data by an Independent Data Monitoring Committee (IDMC).
    Background therapy
    None
    Evidence for comparator
    Prior to this trial, there was some evidence for a benefit of chemotherapy in this setting from non-randomised studies.
    Actual start date of recruitment
    19 Jun 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 260
    Worldwide total number of subjects
    260
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    100
    From 65 to 84 years
    156
    85 years and over
    4

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Recruitment took place from June 2012 to November 2017 at 57 UK centres

    Pre-assignment
    Screening details
    Screening information is not available

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded
    Blinding implementation details
    Not applicable - open-label trial

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Surveillance
    Arm description
    Participants have post-surgery monitoring according to standard practice
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    Chemotherapy
    Arm description
    Participants receive four 21-day cycles of Gemcitabine-Cisplatin or, if GFR 30-49 ml/min, gemcitabine-carboplatin chemotherapy will be given.
    Arm type
    Experimental

    Investigational medicinal product name
    Gemcitabine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder and solvent for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    1000mg/m2 day 1 and day 8 as 30 minute intravenous infusion

    Investigational medicinal product name
    Carboplatin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Carboplatin given instead of cisplatin only for participants with a creatinine clearance of 30-49ml/min. AUC 4.5 or AUC 5 (according to local practice) calculated according to the Calvert formula.

    Investigational medicinal product name
    Cisplatin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    70mg/m2 day 1 as a 4 hour intravenous infusion. If the patient’s calculated or measured GFR was 50-70 mls/min then it was recommended that the cisplatin dose is split over 2 days (35mg/m2 /day) and given on day 1 and 2 if this was standard practice locally.

    Number of subjects in period 1
    Surveillance Chemotherapy
    Started
    129
    131
    Completed
    129
    131

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Surveillance
    Reporting group description
    Participants have post-surgery monitoring according to standard practice

    Reporting group title
    Chemotherapy
    Reporting group description
    Participants receive four 21-day cycles of Gemcitabine-Cisplatin or, if GFR 30-49 ml/min, gemcitabine-carboplatin chemotherapy will be given.

    Reporting group values
    Surveillance Chemotherapy Total
    Number of subjects
    129 131 260
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    57 43 100
        From 65-84 years
    69 87 156
        85 years and over
    3 1 4
    Age continuous
    Units: years
        median (full range (min-max))
    66 (43 to 88) 69 (36 to 85) -
    Gender categorical
    Units: Subjects
        Female
    46 38 84
        Male
    83 93 176
        Not reported
    0 0 0

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Surveillance
    Reporting group description
    Participants have post-surgery monitoring according to standard practice

    Reporting group title
    Chemotherapy
    Reporting group description
    Participants receive four 21-day cycles of Gemcitabine-Cisplatin or, if GFR 30-49 ml/min, gemcitabine-carboplatin chemotherapy will be given.

    Subject analysis set title
    Allocated surveillance
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Intention-to-treat

    Subject analysis set title
    Allocated chemotherapy
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Intention-to-treat

    Subject analysis set title
    Received surveillance
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    Underwent surveillance and did not receive any study drug

    Subject analysis set title
    Received chemotherapy
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    Received at least one dose of study drug

    Primary: Disease-free survival

    Close Top of page
    End point title
    Disease-free survival
    End point description
    Time from randomisation to either first recurrence in the tumour bed, first metastasis, or death from any cause.
    End point type
    Primary
    End point timeframe
    Up to 5 years post-randomisation
    End point values
    Surveillance Chemotherapy
    Number of subjects analysed
    129
    131
    Units: Proportion event-free at 5 years
        number (confidence interval 95%)
    0.45 (0.36 to 0.55)
    0.62 (0.53 to 0.71)
    Statistical analysis title
    Comparison of disease-free survival (ITT)
    Comparison groups
    Surveillance v Chemotherapy
    Number of subjects included in analysis
    260
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.001
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.55
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.38
         upper limit
    0.8

    Secondary: Overall survival

    Close Top of page
    End point title
    Overall survival
    End point description
    Time from random assignment to death from any cause (observations censored at date last known to be alive)
    End point type
    Secondary
    End point timeframe
    Up to 5 years post-randomisation
    End point values
    Surveillance Chemotherapy
    Number of subjects analysed
    129
    131
    Units: Proportion surviving at 5 years
        number (confidence interval 95%)
    0.57 (0.48 to 0.66)
    0.66 (0.57 to 0.74)
    Statistical analysis title
    Comparison of overall survival (ITT)
    Comparison groups
    Surveillance v Chemotherapy
    Number of subjects included in analysis
    260
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.05
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.68
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.46
         upper limit
    1

    Secondary: Metastasis-free survival

    Close Top of page
    End point title
    Metastasis-free survival
    End point description
    Time from randomisation to the first event of distant recurrence or death from any cause
    End point type
    Secondary
    End point timeframe
    Up to 5 years post-randomisation
    End point values
    Surveillance Chemotherapy
    Number of subjects analysed
    129
    131
    Units: Proportion event-free at 5 years
        number (confidence interval 95%)
    0.46 (0.37 to 0.55)
    0.64 (0.55 to 0.73)
    Statistical analysis title
    Comparison of metastasis-free survival (ITT)
    Comparison groups
    Surveillance v Chemotherapy
    Number of subjects included in analysis
    260
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.001
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.55
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.38
         upper limit
    0.79

    Secondary: Time to bladder second primary tumours

    Close Top of page
    End point title
    Time to bladder second primary tumours
    End point description
    Time from randomisation to the first event of non-muscle invasive bladder cancer or muscle invasive bladder cancer
    End point type
    Secondary
    End point timeframe
    Up to 5 years post-randomisation
    End point values
    Surveillance Chemotherapy
    Number of subjects analysed
    129
    131
    Units: Proportion event-free at 5 years
        number (confidence interval 95%)
    0.66 (0.56 to 0.75)
    0.66 (0.57 to 0.75)
    Statistical analysis title
    Comparison of second primary in the bladder (ITT)
    Comparison groups
    Chemotherapy v Surveillance
    Number of subjects included in analysis
    260
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.75
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.93
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.59
         upper limit
    1.46

    Secondary: Late toxicity

    Close Top of page
    End point title
    Late toxicity
    End point description
    Adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4, experienced between 6 months and 2 years post-randomisation
    End point type
    Secondary
    End point timeframe
    From 6 months to 2 years post-randomisation
    End point values
    Received surveillance Received chemotherapy
    Number of subjects analysed
    117
    123
    Units: Participants
        Grade 0
    22
    9
        Grade 1
    38
    57
        Grade 2
    33
    32
        Grade 3
    21
    21
        Grade 4
    1
    3
        Grade 5
    0
    1
        Grade not specified
    2
    0
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    AE reporting throughout treatment up to 13 weeks post-randomisation (end of treatment); SAE reporting in patients receiving chemotherapy up to 30 days after last drug administration.
    Adverse event reporting additional description
    Routine AE data collection at fixed time points after each cycle (or equivalent time points in surveillance group); SAE reporting in chemotherapy group only. Data on late effects reported between 6 and 24 months are included in Endpoints section.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    11.9
    Reporting groups
    Reporting group title
    Received surveillance
    Reporting group description
    Participants who underwent surveillance and did not receive any study drug

    Reporting group title
    Received chemotherapy
    Reporting group description
    Received at least one dose of study drug

    Serious adverse events
    Received surveillance Received chemotherapy
    Total subjects affected by serious adverse events
         subjects affected / exposed
    1 / 133 (0.75%)
    46 / 126 (36.51%)
         number of deaths (all causes)
    62
    44
         number of deaths resulting from adverse events
    0
    0
    Vascular disorders
    Arterial thrombosis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Chest discomfort
         subjects affected / exposed
    0 / 133 (0.00%)
    2 / 126 (1.59%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    chill
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Extravasation
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malaise
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 133 (0.00%)
    5 / 126 (3.97%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Chest pain
         subjects affected / exposed
    0 / 133 (0.00%)
    2 / 126 (1.59%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Localised oedema
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral swelling
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    0 / 133 (0.00%)
    2 / 126 (1.59%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Epistaxis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 133 (0.00%)
    6 / 126 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    6 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cough
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood urea increased
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neutrophil count decreased
         subjects affected / exposed
    0 / 133 (0.00%)
    9 / 126 (7.14%)
         occurrences causally related to treatment / all
    0 / 0
    8 / 9
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Platelet count decreased
         subjects affected / exposed
    0 / 133 (0.00%)
    5 / 126 (3.97%)
         occurrences causally related to treatment / all
    0 / 0
    5 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemoglobin decreased
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Transfusion reaction
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Palpitations
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    0 / 133 (0.00%)
    2 / 126 (1.59%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lethargy
         subjects affected / exposed
    0 / 133 (0.00%)
    2 / 126 (1.59%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Febrile neutropenia
         subjects affected / exposed
    0 / 133 (0.00%)
    4 / 126 (3.17%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Haemorrhoids
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    0 / 133 (0.00%)
    3 / 126 (2.38%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 133 (0.00%)
    4 / 126 (3.17%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    1 / 133 (0.75%)
    6 / 126 (4.76%)
         occurrences causally related to treatment / all
    1 / 1
    6 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 133 (0.00%)
    6 / 126 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    6 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rash macular
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Renal impairment
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal pain
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary retention
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute kidney injury
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Cystitis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neutropenic sepsis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Periodontitis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rhinitis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 133 (0.00%)
    6 / 126 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Orchitis
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    0 / 133 (0.00%)
    3 / 126 (2.38%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperkalaemia
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    0 / 133 (0.00%)
    1 / 126 (0.79%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Received surveillance Received chemotherapy
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    108 / 133 (81.20%)
    126 / 126 (100.00%)
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    8 / 133 (6.02%)
    29 / 126 (23.02%)
         occurrences all number
    8
    29
    Blood creatinine increased
         subjects affected / exposed
    11 / 133 (8.27%)
    20 / 126 (15.87%)
         occurrences all number
    11
    20
    Neutrophil count decreased
         subjects affected / exposed
    1 / 133 (0.75%)
    79 / 126 (62.70%)
         occurrences all number
    1
    79
    Platelet count decreased
         subjects affected / exposed
    4 / 133 (3.01%)
    50 / 126 (39.68%)
         occurrences all number
    4
    50
    White blood cell count decreased
         subjects affected / exposed
    0 / 133 (0.00%)
    8 / 126 (6.35%)
         occurrences all number
    0
    8
    Vascular disorders
    Hypertension
         subjects affected / exposed
    26 / 133 (19.55%)
    32 / 126 (25.40%)
         occurrences all number
    26
    32
    Nervous system disorders
    Dysgeusia
         subjects affected / exposed
    1 / 133 (0.75%)
    10 / 126 (7.94%)
         occurrences all number
    1
    10
    Headache
         subjects affected / exposed
    1 / 133 (0.75%)
    7 / 126 (5.56%)
         occurrences all number
    1
    7
    Lethargy
         subjects affected / exposed
    48 / 133 (36.09%)
    97 / 126 (76.98%)
         occurrences all number
    48
    97
    Peripheral sensory neuropathy
         subjects affected / exposed
    4 / 133 (3.01%)
    22 / 126 (17.46%)
         occurrences all number
    4
    22
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    4 / 133 (3.01%)
    15 / 126 (11.90%)
         occurrences all number
    4
    15
    Localised oedema
         subjects affected / exposed
    8 / 133 (6.02%)
    21 / 126 (16.67%)
         occurrences all number
    8
    21
    Mucosal inflammation
         subjects affected / exposed
    0 / 133 (0.00%)
    7 / 126 (5.56%)
         occurrences all number
    0
    7
    Ear and labyrinth disorders
    Hypoacusis
         subjects affected / exposed
    9 / 133 (6.77%)
    20 / 126 (15.87%)
         occurrences all number
    9
    20
    Tinnitus
         subjects affected / exposed
    7 / 133 (5.26%)
    20 / 126 (15.87%)
         occurrences all number
    7
    20
    Gastrointestinal disorders
    Anaemia
         subjects affected / exposed
    3 / 133 (2.26%)
    34 / 126 (26.98%)
         occurrences all number
    3
    34
    Constipation
         subjects affected / exposed
    2 / 133 (1.50%)
    35 / 126 (27.78%)
         occurrences all number
    2
    35
    Diarrhoea
         subjects affected / exposed
    2 / 133 (1.50%)
    20 / 126 (15.87%)
         occurrences all number
    2
    20
    Dyspepsia
         subjects affected / exposed
    2 / 133 (1.50%)
    11 / 126 (8.73%)
         occurrences all number
    2
    11
    Nausea
         subjects affected / exposed
    13 / 133 (9.77%)
    70 / 126 (55.56%)
         occurrences all number
    13
    70
    Vomiting
         subjects affected / exposed
    5 / 133 (3.76%)
    24 / 126 (19.05%)
         occurrences all number
    5
    24
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    2 / 133 (1.50%)
    9 / 126 (7.14%)
         occurrences all number
    2
    9
    Dyspnoea
         subjects affected / exposed
    6 / 133 (4.51%)
    20 / 126 (15.87%)
         occurrences all number
    6
    20
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    0 / 133 (0.00%)
    18 / 126 (14.29%)
         occurrences all number
    0
    18
    Pruritus
         subjects affected / exposed
    8 / 133 (6.02%)
    23 / 126 (18.25%)
         occurrences all number
    8
    23
    Rash
         subjects affected / exposed
    1 / 133 (0.75%)
    11 / 126 (8.73%)
         occurrences all number
    1
    11
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    12 / 133 (9.02%)
    10 / 126 (7.94%)
         occurrences all number
    12
    10
    Proteinuria
         subjects affected / exposed
    5 / 133 (3.76%)
    9 / 126 (7.14%)
         occurrences all number
    5
    9
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    10 / 133 (7.52%)
    6 / 126 (4.76%)
         occurrences all number
    10
    6
    Infections and infestations
    Urinary tract infection
         subjects affected / exposed
    5 / 133 (3.76%)
    10 / 126 (7.94%)
         occurrences all number
    5
    10
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    1 / 133 (0.75%)
    10 / 126 (7.94%)
         occurrences all number
    1
    10

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    29 Feb 2012
    Addition of mandatory post-operative CT scans of the abdomen and pelvis prior to trial entry for patients whose pre-operative CT scan showed nodal disease. Additional guidance/clarification around chemotherapy dosing.
    07 Sep 2012
    Clarification of the endpoint ‘Invasive recurrence/second primary in the bladder’, split into two separate items: Progression to muscle invasive disease in the bladder; second primary in the bladder. Addition of 3 month abdomen and pelvis CT scan.
    21 Jan 2014
    Addition of translational sample collection, POUT-T. Lowering of age limit in inclusion criteria to ≥16 years of age. Addition of cystoscopy prior to trial entry if not conducted prior to nephro-ureterectomy.
    25 Jun 2015
    Closure of qualitative recruitment sub-study.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Recruitment closed early (of target n=345) on recommendation from the IDMC, since the early stopping rule for the primary endpoint had been met. This was not due to any safety concern. 1 participant who withdrew consent for data use is not reported.

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/32145825
    http://www.ncbi.nlm.nih.gov/pubmed/38350047
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 18 23:22:38 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA